Abstract
Background -Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) exhibit in vitro pulmonary vasodilator activity, but little information is available regarding their effects in the human pulmonary vasculature. Their effects in the human pulmonary circulation and their ability to modulate the pulmonary pressor effects of angiotensin II have therefore been evaluated. Methods -Eight healthy volunteers were studied on three separate occasions. Infusions of either ANP, BNP, or placebo were given for 60 minutes with a concomitant infusion of angiotensin II given for the final 30 minutes. Pulmonary haemodynamics were measured by pulsed wave Doppler echocardiography at baseline (TO), before commencing angiotensin II (T30), and at the end of the infusion period (T60 shown to exhibit in vitro pulmonary vaso-relaxant activity in rats,3 and ANP infusion can reduce pulmonary vascular resistance in patients with cor pulmonale. 4 In addition, the interplay between the natriuretic peptide system and the renin-angiotensin system which is important in terms of hormonal and systemic pressor effects5 has not been studied in the human pulmonary circulation.
We have therefore studied the effects ofANP and BNP on pulmonary vascular tone in humans and their interaction with angiotensin II in the pulmonary circulation. Calculation of PVR does, however, exclude changes in pulmonary capillary wedge pressure and thus we may have overestimated the effects of angiotensin II on pulmonary vascular tone. It has, however, been shown that, for a 10 mm Hg increase in MAP induced by angiotensin II, the associated increase in pulmonary capillary wedge pressure is only 1-7 mm Hg.'0 Thus, in this study the magnitude ofthe MPAP response to angiotensin II (10 8 mm Hg) would be greater than any calculated change in pulmonary capillary wedge pressure (4 9 mm Hg).
Methods
The finding that ANP and BNP have pulmonary vasorelaxant activity and are antagonists of angiotensin II raises some therapeutic possibilities, perhaps in patients with cor pulmonale where the reninangiotensin system is activated." Increasing endogenous levels of ANP and BNP by endopeptidase 24-11 inhibitors may have pulmonary haemodynamic benefits or, alternatively, may suppress overactivity of the renin-angiotensin system by ACE inhibition. This latter strategy has produced conflicting results'21 but, as was the case in congestive heart failure, the true benefit may not be apparent until chronic dosing studies are evaluated.
